

Marked-Up Copy

Serial No:

Amendment Filed on:

3-18-2002

IN THE CLAIMS

Please amend the claims as follows.

--3. (Amended) A formulation according to claim 1 [or 2] which is in single infusion dosage form comprising at least 1300 mg, of the estramustine phosphate.

4. (Amended) A formulation according to [any one of the preceding claims] claim 1 which is in single infusion dosage form comprising at least 950 mg/m², of the estramustine phosphate.

5. (Amended) A formulation according to [any on of the preceding claims] claim 1 wherein the sulfoalkyl ether cyclodextrin is a straight or branched C₁-C₆ sulfoalkyl ether cyclodextrin.

7. (Amended) A formulation according to [any one of the preceding claims] claim 1 for intravenous use.

8. (Amended) A formulation according to [any one of the preceding claims] claim 1 wherein the estramustine phosphate is in the form of a pharmaceutically acceptable salt for intravenous use.

10. (Amended) A formulation according to [any one of the preceding claims] claim 1 for use in the treatment of cancer.

16. (Amended) A product according to claim 14 [or 15] wherein the chemotherapeutic agent is selected from taxane, taxane derivatives, CPT-11, camptothecin

and derivatives thereof, doxorubicin, idarubicin, epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, Sugen SU 6668 and Sugen SU 5416.--

2007-05-03 10:07